Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
- PMID: 29328506
- DOI: 10.1002/cpt.1024
Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Abstract
Atrial fibrillation (AF) is a leading cause of stroke. Oral anticoagulant (OAC) therapy can significantly reduce the risk of stroke in patients with AF, but underuse of OACs for stroke prevention continues to be a serious clinical problem, with significant deleterious impact on outcomes. We review the studies demonstrating OAC underutilization and evaluating strategies for promoting the increased use of OAC therapy for stroke prevention in nonvalvular AF (NVAF) patients, including in special patient populations.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
Comment in
-
Response to: "Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High-Risk Patients With Atrial Fibrillation and Flutter".Clin Pharmacol Ther. 2018 Oct;104(4):615. doi: 10.1002/cpt.1143. Epub 2018 Jul 14. Clin Pharmacol Ther. 2018. PMID: 30006932 No abstract available.
-
Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High-Risk Patients With Atrial Fibrillation and Flutter.Clin Pharmacol Ther. 2018 Oct;104(4):613-614. doi: 10.1002/cpt.1144. Epub 2018 Jul 14. Clin Pharmacol Ther. 2018. PMID: 30006942 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
